Royalty Pharma Plc
$ 47.43
-0.11%
04 Mar - close price
- Market Cap 27,433,949,000 USD
- Current Price $ 47.43
- High / Low $ 47.86 / 47.25
- Stock P/E 26.65
- Book Value 15.11
- EPS 1.78
- Next Earning Report 2026-05-07
- Dividend Per Share $0.88
- Dividend Yield 1.85 %
- Next Dividend Date 2026-03-10
- ROA 0.05 %
- ROE 0.13 %
- 52 Week High 47.86
- 52 Week Low 28.97
About
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Analyst Target Price
$51.56
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-11 | 2025-11-05 | 2025-08-06 | 2025-05-08 | 2025-02-11 | 2024-11-06 | 2024-08-08 | 2024-05-09 | 2024-02-15 | 2023-11-08 | 2023-08-08 | 2023-05-09 |
| Reported EPS | 0.38 | 1.17 | 1.14 | 1.06 | 0.35 | 0.92 | 0.96 | 0.98 | 1.52 | 0.79 | 0.84 | 1.6 |
| Estimated EPS | 1.5 | 1.04 | 1.03 | 0.95 | 0.25 | 0.93 | 0.97 | 0.98 | 1 | 0.77 | 0.81 | 1.27 |
| Surprise | -1.12 | 0.13 | 0.11 | 0.11 | 0.1 | -0.01 | -0.01 | 0 | 0.52 | 0.02 | 0.03 | 0.33 |
| Surprise Percentage | -74.6667% | 12.5% | 10.6796% | 11.5789% | 40% | -1.0753% | -1.0309% | 0% | 52% | 2.5974% | 3.7037% | 25.9843% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-07 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 1.21 |
| Currency | USD |
Previous Dividend Records
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-03-10 | 2025-12-10 | 2025-09-10 | 2025-06-10 | 2025-03-10 | 2024-12-10 | 2024-09-13 | 2024-06-14 | 2024-03-15 | 2023-12-15 |
| Amount | $0.235 | $0.22 | $0.22 | $0.22 | $0.22 | $0.21 | $0.21 | $0.21 | $0.21 | $0.2 |
Next Dividend Records
| Dividend per share (year): | $0.88 |
| Dividend Yield | 1.85% |
| Next Dividend Date | 2026-03-10 |
| Ex-Dividend Date | 2026-02-20 |
Recent News: RPRX
2026-02-26 04:52:06
Entities linked to Royalty Pharma's EVP & CFO, Terrance P. Coyne, sold a total of 34,791 Class A Ordinary Shares in open-market transactions on February 23, 2026. These sales, executed at a weighted average price of $45.3165 per share, were conducted under a pre-established Rule 10b5-1 trading plan adopted in August 2025. The transactions were reported in a Form 4 SEC filing, indicating a negative sentiment for the filing's impact.
2026-02-16 05:51:33
Royalty Pharma reported strong fourth-quarter results, with portfolio receipts reaching $874 million, marking an 18% year-over-year revenue increase. The company also announced four new royalty transactions valued at up to $4.7 billion and provided fiscal 2026 guidance, projecting a 5.5% receipt growth midpoint. This performance caps off what the company described as a landmark year.
2026-02-11 12:57:24
Royalty Pharma (RPRX) reported strong financial performance for Q4 and full year 2025, with significant increases in Portfolio Receipts, Adjusted EBITDA, and Portfolio Cash Flow. The company deployed $2.6 billion in royalty transactions and repurchased $1.2 billion in shares, while also raising its quarterly dividend. For 2026, Royalty Pharma projects continued growth in Portfolio Receipts and anticipates pivotal study results to drive additional value.
2026-02-11 05:53:07
Royalty Pharma (RPRX) reported strong financial results for Q4 and full-year 2025, with Portfolio Receipts up 18% and 16% respectively. The company deployed $2.6 billion into royalty transactions, repurchased 37 million Class A shares for $1.2 billion, and increased its quarterly dividend by 7%. Royalty Pharma also provided positive guidance for full-year 2026 Portfolio Receipts, ranging from $3,275 million to $3,425 million.
2026-02-11 05:53:07
Royalty Pharma (NASDAQ: RPRX) announced strong financial results for 2025, with Portfolio Receipts increasing by 16% to $3,254 million and Adjusted EBITDA rising by 16% to $2,966 million. The company also provided 2026 guidance, expecting Portfolio Receipts between $3,275 million and $3,425 million, representing a 3% to 8% growth in Royalty Receipts. This performance was driven by key products and significant capital deployment into royalty transactions, alongside substantial shareholder returns through share repurchases and dividends.
2026-02-07 08:57:37
Terrance P. Coyne, EVP and CFO of Royalty Pharma plc, sold 237,531 shares of Class A Ordinary Shares between February 2nd and February 4th, 2026, totaling over $10.3 million. These transactions were executed under a 10b5-1 plan and occurred in multiple tranches at varying prices. The article also notes recent company activities including a record funding market year, a dividend increase, and an acquisition.
